DURECT Corporation to Participate in Alcoholic Liver Disease Workshop Today at the 5th Annual NASH Summit

Rhea-AI Summary

DURECT Corporation (Nasdaq: DRRX) announced participation in the 5th Annual NASH Summit workshop from November 29 to December 2, 2021. The session, led by President and CEO James E. Brown, will focus on the severe implications of alcoholic liver disease and the urgent need for effective treatments. This workshop aims to address morbidity and mortality factors associated with the disease. DURECT's drug candidate, Larsucosterol (DUR-928), is in clinical development for alcohol-associated hepatitis and has received Fast Track Designation from the FDA.

CUPERTINO, Calif., Nov. 29, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced it will participate in a workshop today at the 5^th Annual NASH Summit being held virtually from today through December 2, 2021. 

Our President and Chief Executive Officer, James E. Brown, D.V.M. will join hepatology experts in a session to discuss key drivers of morbidity and mortality in alcoholic liver disease, and the critical need to develop effective treatments for the growing volume of people affected by alcoholic liver disease, including alcohol-associated hepatitis.  

Workshop Details:
Workshop:	Workshop D, Broadening Horizons: Investigating Alcoholic Liver Disease in the Context of NASH
Participants:	James Brown, D.V.M., President and CEO of DURECT
	Ashwani Singal, M.D., Professor of Medicine, University of South Dakota
	Winston Dunn, M.D., Transplant Hepatologist, University of Kansas Medical Center
Date/Time:	Today, November 29, 2021, 1:00 p.m. EST

About DURECT Corporation
DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. Larsucosterol (also known as DUR-928), the Company's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved. Full prescribing information about POSIMIR, including the Boxed Warning, can be found at www.posimir.com. For more information about DURECT, please visit www.durect.com and follow us on Twitter https://twitter.com/DURECTCorp.

DURECT Forward-Looking Statement
The statements in this press release regarding the potential for larsucosterol (also known as DUR-928) to treat patients with AH, NASH, multiple acute organ injury, chronic liver diseases and other diseases, ongoing clinical trials of larsucosterol, the potential benefits of Fast Track Designation, and the commercial potential of POSIMIR are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks that the clinical trial of larsucosterol in AH takes longer to conduct than anticipated due to COVID-19 or other factors, the risk that clinical trials of larsucosterol, including AHFIRM, do not confirm the results from earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy or the lifesaving potential of larsucosterol in a statistically significant manner, the risk that Fast Track Designation for larsucosterol in AH may not lead to faster FDA review or an approval, risks that we or a third-party licensee may not commercialize POSIMIR successfully, if at all, and risks related to our ability to obtain capital to fund operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q filed on November 3, 2021 under the heading "Risk Factors."

NOTE: POSIMIR® and SABER® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. Larsucosterol (DUR-928) is an investigational drug candidate under development and has not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication. Full prescribing information for POSIMIR, including its Boxed Warning, can be found at www.posimir.com.

Corporate Contact - Mike Arenberg, DURECT, Chief Financial Officer, +1-408-346-1052, mike.arenberg@durect.com

Media Contact - Mónica Rouco Molina, PhD, LifeSci Communications, +1-929-469-3850, mroucomolina@lifescicomms.com

 

View original content:https://www.prnewswire.com/news-releases/durect-corporation-to-participate-in-alcoholic-liver-disease-workshop-today-at-the-5th-annual-nash-summit-301432641.html

SOURCE DURECT Corporation

FAQ

What is DURECT Corporation's role in the NASH Summit on November 29, 2021?

DURECT Corporation will participate in the 5th Annual NASH Summit workshop discussing alcoholic liver disease, led by CEO James E. Brown.

Who is speaking at the DURECT workshop during the NASH Summit?

The workshop features James E. Brown, D.V.M., and other hepatology experts discussing the need for treatments for alcoholic liver disease.

What is Larsucosterol (DUR-928) being developed for by DURECT Corporation?

Larsucosterol is being developed for the treatment of alcohol-associated hepatitis and has received Fast Track Designation from the FDA.

When does the NASH Summit workshop featuring DURECT take place?

The workshop takes place on November 29, 2021, at 1:00 p.m. EST.

What important health issue does DURECT's workshop aim to address?

The workshop aims to address the morbidity and mortality related to alcoholic liver disease and the need for effective treatments.